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Abstract
The issue of large-scale testing has caught much attention with the advent of high-throughput technologies. In genomic
studies, researchers are often confronted with a large number of tests. To make simultaneous inference for the many tests,
the false discovery rate (FDR) control provides a practical balance between the number of true positives and the number of
false positives. However, when few hypotheses are truly non-null, controlling the FDR may not provide additional
advantages over controlling the family-wise error rate (e.g., the Bonferroni correction). To facilitate discoveries from a study,
weighting tests according to prior information is a promising strategy. A ‘weighted FDR control’ (WEI) and a ‘prioritized
subset analysis’ (PSA) have caught much attention. In this work, we compare the two weighting schemes with systematic
simulation studies and demonstrate their use with a genome-wide association study (GWAS) on type 1 diabetes provided by
the Wellcome Trust Case Control Consortium. The PSA and the WEI both can increase power when the prior is informative.
With accurate and precise prioritization, the PSA can especially create substantial power improvements over the commonly-
used whole-genome single-step FDR adjustment (i.e., the traditional un-weighted FDR control). When the prior is
uninformative (true disease susceptibility regions are not prioritized), the power loss of the PSA and the WEI is almost
negligible. However, a caution is that the overall FDR of the PSA can be slightly inflated if the prioritization is not accurate
and precise. Our study highlights the merits of using information from mounting genetic studies, and provides insights to
choose an appropriate weighting scheme to FDR control on GWAS.
Citation: Lin W-Y, Lee W-C (2012) Improving Power of Genome-Wide Association Studies with Weighted False Discovery Rate Control and Prioritized Subset
Analysis. PLoS ONE 7(4): e33716. doi:10.1371/journal.pone.0033716
Editor: Dan E. Arking, Johns Hopkins University, United States of America
Received September 26, 2011; Accepted February 16, 2012; Published April 9, 2012
Copyright:  2012 Lin, Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding for the WTCCC project was provided by the Wellcome Trust under award 076113. This study was partly supported by National Science
Councils, Taiwan (NSC 99-2628-B-002-061-MY3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wlin@uab.edu
Introduction
The issue of large-scale testing has caught much attention with
the advent of high-throughput technologies such as whole genome
single-nucleotide polymorphism (SNP) arrays. In genome-wide
association studies (GWAS), researchers are often confronted with
a large number of SNPs. Two measures are commonly used to
quantify the overall error rates when making simultaneous
inference for the many SNPs. One is the family-wise error rate
(FWER), defined as the probability of committing at least one
type-I error from among a family of tests. Methods such as the
Bonferroni correction and the Holm’s step-down procedure [1]
can be used to control the FWER. The other commonly used
measure is the false discovery rate (FDR), defined as the expected
ratio of the number of false rejections to the number of total
rejections [2–6]. When the number of true null hypotheses (m0)i s
smaller than the total number of hypotheses (m) (i.e., not all the
null hypotheses are true), the FDR is smaller than or equal to the
FWER [2]. Therefore, given a same nominal control level,
controlling the FDR is less stringent than controlling the FWER.
Controlling the FDR can provide a more practical balance
between the number of true positives and the number of false
positives. The FDR controlling has been widely applied to many
gene expression data sets, in which the proportions of signal genes
(1{m0=m) are usually not small.
For some GWAS where the proportions of signal SNPs are
extremely small (m0*m) [7], controlling the FDR provides no
more benefits than controlling the FWER [8]. Fortunately,
appropriately utilizing information from mounting genetic studies
can improve this. If researchers have informative prior knowledge,
weighting tests according to this prior information can substan-
tially improve the power of a study [8,9]. There are two
approaches to weight tests. One is the ‘weighted FDR control’
(WEI) [10]. The p values are weighted directly based on prior
knowledge, and then the Benjamini and Hochberg’s FDR
controlling [2] or the Storey and Tibshirani’s FDR controlling
[4] is applied to the weighted p values. A study has shown a
prominent benefit of using prior linkage results to weight the p
values of association tests [9]. The second approach is the
‘prioritized subset analysis’ (PSA) [11], which has been applied to
both GWAS [8] and gene expression data analyses [12]. A
researcher first allocates all tests under study into two subsets,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33716based on his/her prior knowledge. A ‘prioritized subset’ comprises
tests likely to be the true positives, and a ‘non-prioritized subset’
comprises the remaining tests. The FDR controlling is then
applied to the two subsets, respectively.
Appropriately utilizing prior information is crucial to exploring
signals, especially when the numbers of tests are going into
millions, such as the scenario in GWAS. Both the WEI and the
PSA have caught much attention for their advantage to facilitate
discoveries from GWAS [8,9,11]. However, the comparison
between them is not clear. In this work, we make a head-to-head
comparison between these two approaches. We compare them
with extensive simulations, and demonstrate their use on a real
GWAS. Our work can provide insights to choose an appropriate
strategy when making simultaneous inference for the many SNPs
in GWAS.
Methods
Whole-genome Single-step FDR Adjustment (WGA)
The WGA is simply the traditional un-weighted FDR control
for GWAS. Suppose that there are a total of m SNPs. Let
P1,P2,   ,Pm fg be the set of observed p values of the m SNPs. To
control the FDR at a desired level, say q , the Benjamini and
Hochberg’s procedure [2] can be applied to this set of p values.
Prioritized Subset Analysis (PSA)
To perform the PSA and the following WEI, prior information
is required to assign each SNP to be ‘more likely a true positive’ or
‘more likely a true negative’. Suppose that we have prior
information coming from our biological knowledge, or from
findings of data other than that in the current study. Let Ui =1if
the ith SNP is located in a chromosomal region supported by prior
information and this SNP is thought to be more likely a true
positive; Ui =0 if this SNP is in a chromosomal region not
supported by prior information and it is thought to be more likely
a true negative. To perform a PSA, we first allocate all SNPs into
two subsets: a ‘prioritized subset’ comprises SNPs likely to be the
true positives (U=1), and a ‘on-prioritized subset’ comprises the
remaining SNPs (U=0). The observed p values of the m SNPs are
accordingly allocated into two subsets. One comprises the p values
of the prioritized SNPs, and the other comprises the p values of the
remaining non-prioritized SNPs. The Benjamini and Hochberg’s
FDR controlling [2] is then applied to these two subsets of p values,
respectively.
Weighted False Discovery Rate Control Procedure (WEI)
There are two weighting schemes for the WEI: ‘binary
weighting’ and ‘general weighting’ [10]. The ‘general weighting’
requires a researcher to assign a weight for each and every SNP
specifically. To have a parallel comparison between the WEI and
the PSA, we here only consider the ‘binary weighting’ for the WEI.
In ‘binary weighting’, SNPs thought to be more likely true
positives (U=1) are all assigned a same weight (w1), and SNPs
thought to be more likely true negatives (U=0) are all assigned
another weight (w0).
Let Wi be the weight assigned to the ith SNP, i=1,…,m. In the
binary weighting scheme, Wi is either w1 or w0. The p values are
weighted according to P 
i ~Pi=Wi, where P 
i is the weighted p
value of the ith SNP. The Benjamini and Hochberg’s FDR
controlling [2] is then applied to the set of weighted p values
P 
1,P 
2,   ,P 
m
  
. To maintain the FDR at a desired level, the set
of weights W1,W2,   ,Wm fg must meet a requirement:
 W W~
Pm
i~1 Wi
 
m~1 [10]. For the weights in the binary
weighting scheme, a researcher can first decide a w1 (or w0),
and work out the other one, w0 (or w1), using the constraint
 W W~1. An alternative is to choose a ratio of the two weights,
r~w1=w0§1, and then obtain w0 with the constraint:
1~  W W~w0|(1{ U U)zw1| U U~w0|(1{ U U)zrw0| U U,
where  U U~
Pm
i~1 Ui
 
m. Therefore, w0~1= 1z(r{1) U U ½  and
w1~r= 1z(r{1) U U ½  .
The choice of r reflects the degree of confidence a researcher has
toward the prior, which is subjective and is specified by the
researcher. (Note that the PSA does not require this parameter,
because the PSA simply allocates all SNPs into two subsets without
specifying any explicit weight.) If the researcher is confident of the
prior information, r can be specified larger. If not, r should be
specified smaller. When r=1, w1~w0, the WEI reduces to the
WGA.
Simulations
We performed simulations to compare the power and the ability
to control the FDR of the WGA, the PSA, and the WEI. To
provide a practical evaluation on these methods when analyzing
GWAS, we followed Li et al. [11] to first simulate GWAS data
with similar linkage disequilibrium (LD) patterns as the HapMap
data [13], and then analyzed the simulated GWAS data sets with
the WGA, the PSA, and the WEI. For the WEI, we followed
Genovese et al. [10] to specify r at 2, 5, or 10.
Simulation program. We used a rapid whole-genome
simulation program, the GWAsimulator [14] (http://biostat.mc.
vanderbilt.edu/wiki/Main/GWAsimulator), to generate GWAS
data sets. The GWAsimulator [14] implements a rapid moving-
window algorithm [15] to simulate whole genome case-control or
population samples. It faithfully generates SNP genotypes that
follow the local LD patterns of the input data. Following Li et al.
[11], we used the phased data of HapMap 60 CEU (CEPH
samples with ancestry from northern and western Europe) founder
subjects as the input data. The total number of SNPs in the input
data is 314,174, after merging the Illumina Sentrix Human-
Hap300 BeadChips (317,503 SNPs) and the HapMap phased data
[11,14].
Setting of the disease model. Following Li et al. [11], we let
six SNPs be the disease variants. Among the six variants, three
have small effects (genotypic relative risk or GRR=1.34) and the
others have relatively large effects (GRR=1.57). We randomly
chose SNPs with minor allele frequencies (MAFs) of 0.25, 0.36,
and 0.33 from chromosomes 6, 10, and 5 respectively, as the three
small-effect SNPs (Locus 1–3). The three large-effect SNPs (Locus
4–6) with MAFs of 0.43, 0.31, and 0.30 were randomly picked
from chromosomes 3, 11, and 4 respectively. This MAF setting
mimics the reported risk loci of type 2 diabetes [16], in which the
minor alleles were treated as risk alleles. Given the genotypes of
the six disease loci, the probability of being affected is
Pr(affectedDgenotype)~ 1zexp({b0{
X6
j~1 bjgj)
hi {1
, where
gj[ 0,1,2 fg is the number of risk alleles at disease locus j, b0 was
chosen to lead to 5% of the population disease prevalence, and bj’s
were chosen to meet the specification for the six GRRs.
We simulated 15,000 replicate data sets. In each replication,
genotypes of 314,174 whole-genome SNPs were generated for
each of 500 unrelated cases and 500 unrelated controls. SNPs with
Hardy-Weinberg exact P value,10{3 in the control group were
excluded. P values were obtained using the one-degree-of-freedom
chi-square test to compare the allele frequencies in cases and
controls. The FDR level was to be controlled at 5%.
Weighting Schemes to False Discovery Rate Control
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e33716We followed Li et al. [11] to define the prioritized subsets
according to the combinations of three factors: (Factor A) the
number of prioritized regions (6, 14, 22); (Factor B) the size of each
prioritized region (2 Mb, 20 Mb); (Factor C) the disease loci to be
prioritized: (i) no disease loci; (ii) Locus 6; (iii) Loci 1 and 6; (iv)
Loci 1, 2, 5, and 6; (v) Loci 4, 5, and 6; (vi) Loci 1, 4, 5, and 6; (vii)
all except Locus 3; (viii) all loci. Factors A and B are directly
related to the precision of a prioritization process, while Factor C
is related to its accuracy.
Results
Simulation Results
FDR evaluations. Figures 1 and 2 present the FDR (the
mean ratio of the number of false rejections to the number of total
rejections, based on the 15,000 replications) of the WGA, the PSA,
and the WEI (r=2, 5, 10) when the prioritized region sizes were
2 Mb and 20 Mb, respectively. Note that the FDR of the PSA was
the overall FDR, obtained by the mean ratio of the number of total
false rejections from the two subsets to the number of total rejections
from the two subsets. The WGA and the WEI had very similar FDRs,
which were under control for all scenarios. For the PSA, accurate
(true disease loci were prioritized) and precise (prioritized regions
were narrower) prioritization led to lower overall FDR. Comparing
the eight scenarios when six 2-Mb regions were prioritized
(Figure 1), the more accurate the prioritization (more true disease
loci were prioritized), the lower the overall FDR. However, within a
same scenario (especially for Scenarios (iv)–(viii)), the overall FDRs
were not as low when more regions unrelated to the disease were
prioritized (14 or 22 regions compared to 6 regions). Comparing
Figure 2 (where six 20-Mb regions were prioritized) with Figure 1
(where six 2-Mb regions were prioritized), the overall FDRs did not
remain as low due to the decreasing precision of the prioritization
(20 Mb compared to 2 Mb). The ability of the PSA to control the
overall FDR depends on the accuracy and precision of the
prioritization. When none of the true disease loci was prioritized
(Scenario (i) of Figures 1 and 2), the overall FDR of the PSA was
inflated to 5.6%. When only one or two disease loci were
prioritized with higher precision (Scenarios (ii) & (iii) of Figure 1),
the overall FDR of the PSA was ‘almost’ under control (still a slight
inflation on the FDR). However, when the one or two disease loci
were prioritized with lower precision (Scenarios (ii) & (iii) of
Figure 2), the overall FDR of the PSA was inflated to 5.3%.
We see that the overall FDR of the PSA can be inflated to 5.6%.
To have a fair evaluation on the power, we deliberately set the
FDR control level at 4.4% (because the ratio of 5% to 5.6% is
approximately equal to the ratio of 4.4% to 5%) for the PSA,
under Scenarios (i)–(iii) for 2 Mb prioritized region size and under
Scenarios (i)–(v) for 20 Mb size. After this adjustment, the overall
FDRs of the PSA method were not larger than 5% (see our
Supporting Information S1).
Power evaluations. Power of detecting a disease locus was
defined as the proportion of ‘successful detections’ of that disease
locus among all the 15,000 replications, in which a ‘successful
detection’ was defined as ‘declaration of significance for at least
one SNP within one Mb from the disease locus’ (following the
definition by Li et al. [11]). Figures 3 and 4 present the power
comparisons between the WGA, the PSA, and the WEI (r=2,5,
10) when six 2-Mb regions and when six 20-Mb regions were
prioritized, respectively. Our Supporting Information S1 shows
the results when 14 or 22 regions were prioritized, each region
with a size of 2 Mb or 20 Mb. Note that the power was compared
(Figures 3, 4, and Supporting Information S1) with the adjustment
of FDR for the PSA (that is, the FDR control level was deliberately
set at 4.4% for the PSA, under Scenarios (i)–(iii) for 2 Mb
prioritized region size and under Scenarios (i)–(v) for 20 Mb size.).
The accuracy of a prioritization process directly affects the
relative power performance of the three methods. When the
regions encompassing the true disease loci were prioritized, the
most powerful method was the PSA, then was the WEI (r=10).
The WEI with a larger r was more powerful than the WEI with a
smaller r (see Scenarios (ii)–(viii) of Figures 3 & 4, where at least
one disease locus was prioritized). When the regions encompassing
the true disease loci were not prioritized, the power loss of the PSA
and the WEI was almost negligible. The WEI with a larger r
suffered from more power loss than the WEI with a smaller r (see
Scenario (i) of the last figure in the Supporting Information S1,
where no disease loci were prioritized).
Furthermore, the precision of a prioritization process also
influences the power of the PSA and the WEI. Regarding the size
of each prioritized region (2 Mb or 20 Mb) and the number of
prioritized regions (6, 14, or 22), the power improvement of the
PSA and the WEI was not as prominent when the prioritization
was not as precise, i.e., a wider region around a true disease locus
was prioritized (20 Mb compared to 2 Mb), or more regions
unrelated to the disease were prioritized (22 or 14 regions
compared to 6 regions).
Application to the Wellcome Trust Case Control
Consortium (WTCCC) Data
We further demonstrate the WGA, the PSA, and the WEI with
a GWAS on type 1 diabetes (T1D). The data set was provided by
the Wellcome Trust Case Control Consortium (WTCCC) [17]
that included 2,000 T1D cases and 3,000 controls. Subjects were
living within England, Scotland, and Wales (‘Great Britain’). The
vast majority had self-identified themselves as white Europeans
[17]. The control subjects were from 1958 British Birth Cohort
(1,500 subjects) and UK Blood Services sample (1,500 subjects).
After excluding subjects identified as having recent non-European
ancestry, there were 1,963 T1D cases and 2,938 controls [17].
Subjects were genotyped using the Affymetrix GeneChip 500 K
arrays comprising 500,568 SNPs. According to the WTCCC
criteria [17], 459,653 SNPs passed the quality control filters. We
further removed 578 SNPs with poor clustering and retained
459,075 SNPs.
WGA. For each SNP, we used the p value obtained from the
genotypic test. Controlling the FDR at 5%, 12 independent
association signals were declared to be significant with the WGA
(an association signal was identified given more than a single
significant SNP within 2 Mb). Figure 5 and Table 1 show the 12
signals that can be mapped to 12 genes. Among them, five were
declared to be significant when the Bonferroni correction was used
to control the FWER at 5%.
Prioritization process. To perform the PSA and the WEI,
prior information is required to assign each SNP to be ‘more likely
a true positive’ or ‘more likely a true negative’. We collected the
information by searching for publications with ‘gene’, ‘association’,
and ‘type 1 diabetes’ in their titles. PubMed shows 89 publications
meeting this searching criterion. Among them, we used the studies
independent of the WTCCC project and published prior to the
WTCCC publication [17]. Table 2 lists the genes that are
previously reported to be associated with T1D. We obtained the
physical position of each gene (listed in Table 2) from the Gene
Location website (http://genecards.weizmann.ac.il/geneloc/
index.shtml). SNPs within 1 Mb from each gene were prioritized
(so the size of each prioritized region was 2 Mb). When prioritizing
SNPs according to prior information, there is no stringent criterion
for the sizes of prioritized regions (we will discuss this in the
Weighting Schemes to False Discovery Rate Control
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e33716Figure 1. FDR of the WGA, the PSA, and the WEI (r=2, 5, 10) when the prioritized region sizes were 2 Mb (without adjustment to the
PSA).
doi:10.1371/journal.pone.0033716.g001
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e33716Figure 2. FDR of the WGA, the PSA, and the WEI (r=2, 5, 10) when the prioritized region sizes were 20 Mb (without adjustment to
the PSA).
doi:10.1371/journal.pone.0033716.g002
Weighting Schemes to False Discovery Rate Control
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e33716Figure 3. Power comparison between the WGA, the PSA, and the WEI (r=2, 5, 10) when six 2-Mb regions were prioritized (with
adjustment to the PSA). A locus with parentheses indicates that the disease locus was included in the prioritized subset.
doi:10.1371/journal.pone.0033716.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e33716Figure 4. Power comparison between the WGA, the PSA, and the WEI (r=2, 5, 10) when six 20-Mb regions were prioritized (with
adjustment to the PSA). A locus with parentheses indicates that the disease locus was included in the prioritized subset.
doi:10.1371/journal.pone.0033716.g004
Weighting Schemes to False Discovery Rate Control
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e33716Discussion). However, in general, a wider region should be
prioritized for a linkage peak than that for an association signal,
because linkage is a coarse mapping while association is a fine
mapping. In this data analysis, our prior information came from
previous association studies on T1D, and therefore we chose a
moderate prioritization size for each region 22 Mb. Totally, we
prioritized 6,914 SNPs and left the remaining 452,161 SNPs in the
non-prioritized subset. A list of the prioritized SNPs is available
upon request.
PSA. To perform a PSA, the genotypic p values of the 459,075
SNPs were accordingly allocated into two subsets. The FDR was
to be controlled at 5%. The Benjamini and Hochberg’s FDR
controlling [2] was applied to the two subsets of p values,
respectively. Finally, 15 genes were declared to be significant (see
Figure 5 and Table 1). Among them, nine genes came from the
Figure 5. Manhattan plot for the T1D data set. The x-axis lists the chromosome numbers, and the y-axis presents {log10 p value ðÞ . The red
points label the significant genes identified by each method (from top to bottom: the Bonferroni correction to control the FWER at 5%, the WGA to
control the FDR at 5%, and the PSA to control the FDR at 5%). This figure was plotted with the R package ‘gap’ [31].
doi:10.1371/journal.pone.0033716.g005
Weighting Schemes to False Discovery Rate Control
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IL2RA, INS, CALD1, and PD-1. The last three were not identified
as significant genes with the WGA method. Being allocated into
the prioritized subset, they (INS, CALD1, and PD-1) had a chance
to be identified as significant genes. We further evaluated whether
the FDR was well controlled in the prioritized subset. We
permuted the phenotypes 10
4 times and obtained 10
4 null p values
for each of the 6,914 SNPs. Then we estimated the number of false
positives by counting the number of null p values more extreme
(i.e., smaller) than 2:59|10{3, the largest P value of the
association signals in the prioritized subset. In this way, we
obtained an estimated permutation-based FDR [18] at 3.64%, still
less than the FDR control level of 5%. In fact, several studies
published later than the WTCCC paper [17] also supported the
association of these three genes with T1D (INS [19–22], CALD1
[23,24], and PD-1 [25,26]).
WEI. To perform a WEI, in addition to the prior information
used for the PSA, a ratio of the two weights (r) was specified at 2,
5, and 10, respectively. In this T1D study, the proportion of SNPs
thought to be more likely true positives among all the SNPs was
 U U~
Pm
i~1 Ui
 
m~6914=459075~0:015. With a specified r,t h e
weight given to SNPs thought to be more likely true positives was
w1~r= 1z(r{1) U U ½  , and that given to SNPs thought to be more
likely true negatives was w0~1= 1z(r{1) U U ½  .T h ep values were
then weighted according to P 
i ~Pi=Wi,w h e r ePi and P 
i were
respectively the original and weighted p values of the ith SNP,
and Wi[ w0,w1 fg . We used the Benjamini and Hochberg’s
method [2] to control the FDR at 5%. When r was specified at
2, the WEI identified the same 12 genes as the WGA. When r was
specified at 5 or 10, the WEI identified one more gene – INS (see
Table 1).
Discussion
The PSA and the WEI both require prior knowledge to boost
the power of detecting signals. Prior knowledge can be collected
from previous independent studies that were not based on the
same data of the current working study. It should be searched before
seeing the analysis results of the individual tests in the current
study. Both the PSA and the WEI have caught much attention in
the era of high-throughput genomics, for their improvement on
the FDR control. With the advancement of biological technolo-
gies, we now can obtain substantial genomic data with decreasing
costs. To facilitate discoveries from more and more hypothesis
tests, clarifying the merits and limitations of the PSA and the WEI
is important.
The PSA and the WEI both can increase power when the prior
is informative. As shown in our simulation, the PSA can especially
create substantial power improvements given accurate and precise
prioritization. When researchers fail to prioritize some true disease
loci, the power loss of the PSA and the WEI is almost negligible.
Like the WGA, the WEI has a solid theoretical background [10]
and a good ability to control the FDR at the desired level (Figures 1
and 2).
Although the PSA can increase much power when the prior is
informative, its overall FDR can be slightly inflated if the
prioritization is not accurate and precise. In our simulation, the
overall FDR of the PSA was obtained by the mean ratio of the
number of total false rejections from the two subsets to the number of
total rejections from the two subsets, based on 15,000 replications.
Because the Benjamini and Hochberg’s FDR controlling [2] is
applied to the prioritized and the non-prioritized subsets respectively,
the overall FDR of the PSA is not guaranteed to be controlled at the
desired level even when the numbers of SNPs in the two subsets
Table 1. Results of the T1D data set.
Gene
1 Chromosome Bonferroni
2
WGA,
WEI (r=2)
WEI
(r=5, 10) PSA WTCCC SNP
3 Genotypic P value
4
Supported by
later studies
5
HLA* 6p21 V V V V rs9272346 5:47|10{134 [32–34]
PTPN22* 1p13 V V V V rs6679677 5:43|10{26 [22,35–49]
SH2B3 12q24 V V V V rs17696736 1:51|10{14 [50]
ERBB3 12q13 V V V V rs11171739 9:71|10{11 [51]
KIAA0350 16p13 V V V V rs12708716 4:92|10{7 [52,53]
CD69 12p13 V V V rs11052552 7:24|10{7 [54]
ADAD1 4q27 V V V rs17388568 3:27|10{6 [55–57]
NeuroD* 2q32 V V V rs10206282 7:89|10{6 [58,59]
CTLA4* 2q33 V V V rs231726 1:78|10{5 [19,60–63]
CCR3 3p21 V V V rs2157057 2:20|10{5 [64]
IL-10* 1q31–q32 V V V rs12061474 2:66|10{5 [65–70]
IL2RA* 10p15–p14 V V V rs2104286 4:32|10{5 [71–76]
INS* 11p15 V V rs6578252 2:82|10{4 [19–22]
CALD1* 7q33 V rs2250603 9:53|10{4 [23,24]
PD-1* 2q37 V rs10192057 2:59|10{3 [25,26]
Number of significant genes 5 12 13 15
1 *: being allocated in the prioritized subset.
2V: significant.
3The WTCCC SNP showing the strongest association evidence in that region.
4The p value of the genotypic test of the WTCCC SNP showing the strongest association evidence in that region.
5That association signal is supported by later studies that have NOT been selected as our prior information (in Table 2).
doi:10.1371/journal.pone.0033716.t001
Weighting Schemes to False Discovery Rate Control
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precise) were prioritized, the overall FDRs of the PSA were inflated
under Scenarios (i)–(iv) (not accurate) despite ,49,000 SNPs in the
prioritized subset and ,265,000 SNPs in the non-prioritized
subset. This is because when the prioritization is not accurate and
precise, the number of true positives from the prioritized subset
can be small (or the number of false positives can be large). This
can inflate the overall FDR of the PSA.
There is no stringent criterion for the sizes of prioritized regions,
when prioritizing SNPs according to prior information. Given a
linkage peak or an association signal based on prior studies,
prioritizing a narrow region may miss the true disease loci and lose
the accuracy, while prioritizing a wide region may lose the
precision. It is not easy to conclude how wide a region should be
prioritized. Although the determination for a region size is
somewhat ad hoc, a general principle is to estimate the
permutation-based FDR [18] after performing the PSA. This
can empirically evaluate whether the FDR within each subset is
well controlled.
The WEI can be equipped with ‘general weighting scheme’,
although we only evaluated the ‘binary weighting scheme’ for its
parallel comparison with the PSA. For the general weighting
scheme, each test is assigned a specific weight, not only either w1
or w0. In this way, the WEI is more flexible than the PSA in the
sense that the weights can be assigned in a continuous scale. To
mimic this flexibility, the PSA can extend its original concept to
allocate SNPs into more than two subsets. However, this will
inevitably increase the possibility of unsatisfactory FDR control.
In addition to conventional GWAS, weighting tests can provide
insights to rare variant detection. In the past several years, GWAS
have identified hundreds of common genetic variants (minor allele
frequency (MAF).5%) for complex human diseases [27]. However,
these common variants can only explain a small proportion of
heritability. The field of genetic epidemiology is shifting toward the
study of low-frequency (MAF 1%–5%) and rare variants
(MAF,1%), which are thought to have larger effect sizes than
common variants [28]. Unfortunately, rare variants are difficult to
detect due to their low frequencies. Recently, a weighted-Holm
procedure was shown to substantially improve the power of
detecting rare variants with large genetic effects [29]. Furthermore,
a study has shown that low-frequency variants can be identified by
up-weightingSNPs with lower MAFs and then performingtheFDR
control [30]. Appropriately weighting genetic variants according to
their MAFs canfacilitatethedetectionofrare variants. Applyingthe
PSA and the WEI to this topic deserves further investigation.
Supporting Information
Supporting Information S1 FDR of the WGA, the PSA,
and the WEI (r=2, 5, 10) when the prioritized region
sizes were 2 Mb and 20 Mb (with adjustment to the
PSA), respectively; power comparison between the WGA,
the PSA, and the WEI (r=2, 5, 10) when 14 2-Mb, 14 20-
Mb, 22 2-Mb, and 22 20-Mb regions were prioritized
(with adjustment to the PSA), respectively.
(DOC)
Table 2. Prior knowledge: genes that are previously reported to be associated with type 1 diabetes.
Gene Chromosome Start base pair
1 End base pair
1 Publications prior to the WTCCC paper
PTPN22 1 114356433 114414381 [77–79]
IL-10 1 206940947 206945839 [80]
IL1R1 2 102681004 102744178 [81]
NeuroD 2 182537815 182545603 [82]
CD28 2 204571198 204738683 [83]
CTLA4 2 204732509 204738683 [83–90]
SLC11A1
2 2 219246752 219261617 [91,92]
PD-1 2 242792033 242801060 [93]
DBP 4 72607410 72669758 [94]
MIC-A 6 31367561 31433586 [95]
HLA-DRB1 6 32546546 32557625 [96,97]
HLA-DQA1 6 32595956 32714992 [97]
HLA-DQB1 6 32627244 32731330 [97]
SUMO4 6 149721495 149722182 [98]
MTH1 7 2281857 2291004 [99]
CALD1 7 134429003 134655480 [100]
IL2RA 10 6052652 6104333 [101]
INS 11 2181009 2182571 [102,103]
IL-18 11 112013974 112034840 [85,104]
VDR 12 48235320 48336831 [105–107]
OAS 12 113344582 113369991 [108]
HSD11B2 16 67465036 67471456 [109]
ICAM-1 19 10381517 10397291 [110,111]
1The physical positions were obtained from the Gene Location website (http://genecards.weizmann.ac.il/geneloc/index.shtml).
2Other aliases: LSH, NRAMP, NRAMP1.
doi:10.1371/journal.pone.0033716.t002
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